Teleflex Incorporated have announced that the company has received reimbursement approval from the Central Social Insurance Medical Council of Japan (Chuikyo) for the UroLift System for patients who require treatment for benign prostatic hyperplasia (BPH).
The UroLift System treatment is a minimally invasive approach to treating BPH, commonly known as an enlarged prostate, a condition that causes bothersome urinary symptoms in men. Performed as a same-day outpatient procedure, the UroLift System can help improve quality of life, and offers lasting relief from symptoms with minimal downtime for patients, according to the company.
“The UroLift System is a major advancement in the treatment of BPH and can positively impact patients’ quality of life. We are very excited to have this technology available soon in Japan and look forward to its use in treating our patients,” said Satoru Takahashi, the professor and chairman in the Department of Urology, Nihon University School of Medicine, Tokyo, Japan.
The newly approved reimbursement for the UroLift System in Japan goes into effect 1 April 2022. Teleflex currently plans to enroll Japan’s Pharmaceuticals and Medical Devices Agency (PMDA-mandated), post-market clinical study to expand its already robust clinical data on the efficacy of the UroLift System and support widespread adoption of the UroLift System in Japan.
